Core Viewpoint - Jingxin Pharmaceutical has signed a patent licensing agreement with Gedeon Richter Plc, allowing the company to develop, manufacture, and commercialize the hydrochloride formulation and active pharmaceutical ingredient (API) of Calypsol in mainland China [1] Company Summary - The agreement grants Jingxin Pharmaceutical exclusive rights to use the patented technology for Calypsol in the specified region [1] - Calypsol is classified as an atypical antipsychotic drug, functioning as a partial agonist of dopamine D2 and D3 receptors [1] - The drug is primarily indicated for the treatment of adult schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and major depressive disorder (MDD) as an adjunct in antidepressant therapy [1]